SyneuRx International (Taiwan) Corp.

Chairman: Dr. Guochuan Emil Tsai
Established Date: 2013/04/02 
Tel: 886-2-7742-2699
Fax: 886-2-2697-2629
Address: 20F-10, No.99, Sec.1, Xintai 5th Rd, Xizhi Dist., New Taipei City 221, Taiwan


Company Profile:

SyneuRx is pioneering and developing revolutionary, completely new classes of drug to answer the unmet medical needs in central nervous system (CNS) disorders. Our candidate drugs hold great promise to fast track the development process and reach a dominant position in the CNS drug market quickly. The candidate drugs in our pipeline represent a rare opportunity with low risk and potentially high return.

Our multi-national team is located in both the US and Greater China regions. The combined innovations, resources and production from US and Asia are the strength of our team. The corporation was founded in 2013 by several Taiwanese/Americans with the goal to realize the scientific breakthroughs to develop novel CNS drugs for mental/behavior health. The experienced team has developed and tested multiple candidate drugs in human with unexpected good efficacy and negligible side effects. They bring exceptional technical expertise and business experience to the enterprise to promise the success of launching new drugs in relatively short period of time.

New Drug in Development:

  • The Pipeline under Clinical Development

New Drug




adolescent schizophrenia
(orphan, first in new class)


SND-12 an combinational therapy on refractory schizophrenia (breakthrough therapy, orphan drug, new indication, first in new class) II/III


an add-on therapy of schizophrenia (breakthrough therapy, new indication, first in new class)



The Pipeline Planned to be Launched*

New Drug Indication Phase
SND-14 early dementia
(new indication, first in new class)
SNG-12 major depression
(first in new class)

refractory major depression 
(new indication, first in new class)



* R & D plans may change